HOUSTON, Oct. 26, 2016 /PRNewswire/ -- A class-action
lawsuit filed against pharmaceutical giant Mylan Inc. (NASDAQ: MYL)
seeks damages for consumers victimized by the company's cutthroat
sales and marketing tactics related to controversial price
increases for Mylan's EpiPen injectors.
The lawsuit filed by The Lanier Law Firm and Sharp Law on behalf
of consumers who have purchased EpiPen injectors charges that Mylan
began a series of aggressive price increases shortly after it
acquired the rights to sell the EpiPen in 2007. Mylan required
consumers to purchase the EpiPen in pairs and raised the retail
price from $57 in 2007 to more than
$600 today, even though
pharmaceutical industry sources estimate each injector can be
produced for less than $30.
"Mylan CEO Heather Bresch knows
that good hardworking Americans will do anything to protect loved
ones from a deadly allergic reaction that could happen at any
time," said attorney Mark Lanier,
founder of The Lanier Law Firm. "This company's attempt to saddle
consumers, insurance companies, Medicare and Medicaid with the bill
for its outrageously overpriced product is indefensible."
For more information about the lawsuits, visit
www.lanierlawfirm.com.
Mylan closely protects its monopoly on the EpiPen, which
delivers life saving medicine to fend off allergic reactions. The
company's pricing scheme results in excessive out-of-pocket
expenses for the uninsured and those with high-deductible health
insurance. Mylan is currently under investigation by the House
Committee on Oversight and Government Reform, the Securities and
Exchange Commission and state regulatory authorities for its EpiPen
pricing scheme.
The lawsuit, Rosetta Serrano
and Shannon Clements et al. vs.
Mylan N.V., Mylan Specialty L.P., is filed in the U.S. District
Court for the District of Kansas
(Case No. 16-2711) on behalf of potentially thousands of consumers
who have purchased an EpiPen.
With offices in Houston,
New York and Los Angeles, The Lanier Law Firm is committed
to addressing client concerns with effective and innovative
solutions in courtrooms across the country. The firm is composed of
outstanding trial attorneys with decades of experience handling
cases involving pharmaceutical liability, asbestos exposure,
commercial litigation, product liability, personal injuries,
maritime law, and sports and entertainment law.
For more information, contact J.D.
Cargill at 1.800.723.3216 or
jdc@lanierlawfirm.com.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/epipen-maker-mylan-hit-with-class-action-lawsuit-300351794.html
SOURCE Lanier Law Firm